Moderna Stock Plummets 18% After Cancer-Vaccine Data Leak

Moderna shares plunged 18% after reported results for its cancer vaccine, developed with Merck, circulated ahead of a planned conference presentation, according to Barron's. The sell-off hit one of the week's sharpest single-stock drops, driven by the early release of data the companies had not yet formally presented.

The premature circulation is the catalyst here. Data that reaches the market before its scheduled debut strips out the controlled context of a formal presentation, leaving traders to price in unverified results all at once. An 18% move signals the market read the leaked figures as disappointing. That is interpretation, not confirmed fact, since the full results remain unpresented.

The drop landed in a volatile week. Barron's noted that chip stocks rebounded Friday into the close, with buy-the-dip calls continuing even as AI sentiment stays choppy. Moderna's slide ran against that bounce, which suggests the move was stock-specific rather than part of a broad market sell-off. That framing is analytical inference from the contrast in Barron's reporting.

The Merck partnership matters for context: the cancer vaccine is a joint program, so the formal presentation will test whether the leaked numbers hold up under full disclosure.